Replies to post #861 on Ampio Pharmaceuticals Inc (AMPE)

[TJG]

The PR today says they will be at the Roth Capital Forum on the 28 of this month to discuss the following:

The Company's presentation will (i) review preliminary results from the randomized, controlled study o intravenous Ampion(TM) for treatment of hospitalized COVID-19 infected adult patients requiring supplemental oxygen and (ii) further discuss its future COVID-19 plans. Ampion addition to standard of care ("SOC") was compared to patients treated with the SOC including anti-viral therapy ("remdesivir").

They will I am sure also discuss the current trial of the nebulizer and that should get reported after the presentation.

If you check remdesivir was approved by the FDA and the Ampion results were better then theirs were..so it would seem that FDA approval for Ampion both intravenous and nebulizer methods should be as well.